Biogen shares surge 8.19% after hours on Q4 earnings beat driven by Leqembi, Skyclarys, and Zurzuvae growth.

Biogen surged 8.19% in after-hours trading following the release of better-than-expected fourth-quarter earnings and revenue results. The company reported adjusted EPS of $1.99, exceeding the $1.59 consensus, while revenue reached $2.28 billion, above the $2.20 billion estimate. Strong performance in growth products, including Alzheimer’s drug Leqembi (with $134 million in in-market sales), Skyclarys (Friedreich’s ataxia), and Zurzuvae (postpartum depression), offset declines in multiple sclerosis revenue. The stock hit a 52-week high during regular hours and continued upward in after-hours trading, driven by positive earnings momentum, resilient growth in key therapies, and a revised 2026 outlook with higher earnings guidance. The rise aligns with the company’s emphasis on execution and financial discipline amid a challenging MS market.